LIR Life Sciences Corp. SKNY
CNSX
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 8.50K | 12.20K | 7.30K | -- | -- |
| Gross Profit | -8.50K | -12.20K | -7.30K | -- | -- |
| SG&A Expenses | 2.86M | 2.43M | 1.73M | -- | -- |
| Depreciation & Amortization | 2.90K | 3.70K | 2.80K | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.10M | 2.49M | 1.74M | -- | -- |
| Operating Income | -3.10M | -2.49M | -1.74M | -- | -- |
| Income Before Tax | -3.43M | -2.82M | -1.96M | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.43 | -2.82 | -1.96 | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.43M | -2.82M | -1.96M | -- | -- |
| EBIT | -3.10M | -2.49M | -1.74M | -- | -- |
| EBITDA | -3.09M | -2.49M | -1.59M | -- | -- |
| EPS Basic | -0.12 | -0.11 | -0.08 | -- | -- |
| Normalized Basic EPS | -0.08 | -0.07 | -0.05 | -- | -- |
| EPS Diluted | -0.12 | -0.11 | -0.08 | -- | -- |
| Normalized Diluted EPS | -0.08 | -0.07 | -0.05 | -- | -- |
| Average Basic Shares Outstanding | 103.96M | 94.29M | 84.43M | -- | -- |
| Average Diluted Shares Outstanding | 103.96M | 94.29M | 84.43M | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |